Top
Summary
All studies
Cases
RCTs
Peer-reviewed
All outcomes

Feedback
Analgesics⏵
Antiandrogens⏵
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins⏵

Other
Feedback
Home
Top
All iota‑carrageenan studies
 
Feedback
Home
c19early.org COVID-19 treatment researchIota-carrageenanIota-carragee.. (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta
Home Adoption Other Treatments

Outcomes in COVID-19 iota-carrageenan studies

Home
Tweet
Share
@CovidAnalysis
StudiesStudies
Adoption
FeedbackFeedback
All studies   Cases   RCTs   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies 80% 1 394 Improvement, Studies, Patients Relative Risk Cases 80% 1 394 RCTs 80% 1 394 Prophylaxis 80% 1 394 Iota-carrageenan for COVID-19 c19early.org Sep 2023 Favorscarrageenan Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CARR-COV-02 Figueroa (DB RCT) 80% 0.20 [0.05-0.78] symp. case 2/196 10/198 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.035 Prophylaxis 80% 0.20 [0.05-0.78] 2/196 10/198 80% lower risk All studies 80% 0.20 [0.05-0.78] 2/196 10/198 80% lower risk 1 iota-carrageenan COVID-19 study c19early.org Sep 2023 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.035 Effect extraction pre-specified(most serious outcome) Favors carrageenan Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CARR-COV-02 Figueroa (DB RCT) 80% 0.20 [0.05-0.78] symp. case 2/196 10/198 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.035 Prophylaxis 80% 0.20 [0.05-0.78] 2/196 10/198 80% lower risk All studies 80% 0.20 [0.05-0.78] 2/196 10/198 80% lower risk 1 iota-carrageenan COVID-19 case result c19early.org Sep 2023 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.035 Favors carrageenan Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CARR-COV-02 Figueroa (DB RCT) 80% 0.20 [0.05-0.78] symp. case 2/196 10/198 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.035 Prophylaxis 80% 0.20 [0.05-0.78] 2/196 10/198 80% lower risk All studies 80% 0.20 [0.05-0.78] 2/196 10/198 80% lower risk 1 iota-carrageenan COVID-19 Randomized Controlled Trials c19early.org Sep 2023 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.035 Effect extraction pre-specified(most serious outcome) Favors carrageenan Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CARR-COV-02 Figueroa (DB RCT) 80% 0.20 [0.05-0.78] symp. case 2/196 10/198 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.035 Prophylaxis 80% 0.20 [0.05-0.78] 2/196 10/198 80% lower risk All studies 80% 0.20 [0.05-0.78] 2/196 10/198 80% lower risk 1 iota-carrageenan COVID-19 peer reviewed studies c19early.org Sep 2023 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.035 Effect extraction pre-specified(most serious outcome) Favors carrageenan Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CARR-COV-02 Figueroa (DB RCT) 80% 0.20 [0.05-0.78] symp. case 2/196 10/198 Improvement, RR [CI] Treatment Control Iota-carrageenan COVID-19 outcomes c19early.org Sep 2023 Favors carrageenan Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Tweet
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0